Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.02
+0.03013.04%
Pre-market: 1.020.00000.00%08:11 EDT
Volume:1.02M
Turnover:962.26K
Market Cap:59.79M
PE:-3.57
High:1.02
Open:0.8800
Low:0.8100
Close:0.9899
Loading ...

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

PR Newswire
·
17 Mar

IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study

TIPRANKS
·
10 Mar

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

PR Newswire
·
10 Mar

IceCure Medical files for regulatory approval of cryoablation system in Israel

TIPRANKS
·
24 Feb

Icecure Submits Filing for Regulatory Approval of Its Next-Generation Xsense™ Cryoablation System in Israel

THOMSON REUTERS
·
24 Feb

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

PR Newswire
·
24 Feb

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

Simply Wall St.
·
18 Feb

IceCure Medical Awaits FDA Decision as ProSense® Gains Attention

TIPRANKS
·
04 Feb

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

PR Newswire
·
04 Feb

IceCure Medical Seeks to Expand in China with ProSense® Cryoablation System

TIPRANKS
·
27 Jan

Icecure Files for Regulatory Approval of Prosense® Cryoablation System in China

THOMSON REUTERS
·
27 Jan

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

PR Newswire
·
27 Jan

Icecure Medical : Entered Into Equity Distribution Agreement With Maxim Group Llc

THOMSON REUTERS
·
13 Jan

Icecure Medical Ltd: May Offer, Sell Ordinary Shares of up to $13.96 Mln From Time to Time

THOMSON REUTERS
·
13 Jan

IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025

TIPRANKS
·
13 Jan

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

PR Newswire
·
13 Jan

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

Simply Wall St.
·
08 Jan

BRIEF-Icecure Medical Regains Full Nasdaq Compliance With Nasdaq Minimum Closing Bid Price Rule

Reuters
·
06 Jan

IceCure Medical Regains Nasdaq Compliance, Securing Market Position

TIPRANKS
·
06 Jan

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

PR Newswire
·
06 Jan